/
LYEL
$12.75+$1.14 (+9.82%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$270.9M
23M shares
52-week range
$8.63 – $45.00
11% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-307.45
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $657.0K | $7.8M | $10.7M | $84.7M | $130.0K | $61.0K | $36.0K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $11.5M |
| Gross profit | $657.0K | $7.8M | $10.7M | $84.7M | $130.0K | $61.0K | −$11.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -31952.8% |
| R&D | $63.6M | $182.2M | $138.7M | $159.2M | $182.9M | $171.6M | $158.7M |
| Operating income | −$102.1M | −$211.9M | −$214.8M | −$187.1M | −$247.0M | −$358.8M | −$203.8M |
| EBITDA | −$100.8M | −$215.4M | −$236.6M | −$165.1M | −$214.4M | −$200.6M | −$262.9M |
| Net income | −$129.4M | −$204.5M | −$250.2M | −$183.1M | −$234.6M | −$343.0M | −$274.4M |
| Net margin | -19692.1% | -2636.3% | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| EPS (diluted) | -0.53 | -0.84 | -1.03 | -0.74 | -0.93 | -1.31 | -16.06 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12857 | $-7.68 | $-8.42–$-6.95 | 5 |
| 2027 | $9M | $-7.99 | $-10.46–$-5.52 | 5 |
| 2028 | $57M | $-7.07 | $-8.86–$-5.40 | 3 |
| 2029 | $190M | $-5.12 | $-5.12–$-5.12 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.35
Price
$12.75
Implied downside
-97%
Peer comparison
Lyell Immunopharma, Inc. Common Stock
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
www.lyell.com- Employees
- 161
- IPO / List date
- Jun 17, 2021
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds LYEL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 116,411 | $2.3M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-06-02 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded LYEL yet.
